# pTau-217 Blood Tests Go Direct to Consumer as Anti-Amyloid Stays Early Innings - The Neuro & Alzheimer's Pipeline - Week of June 28, 2026 > Neuro and Alzheimer's pipeline newsletter for the week of June 22-28, 2026. A prescribing clinician says pTau-217 blood tests are now sold direct-to-consumer by quite a few labs, opening a validated-versus-unvalidated quality split underneath a real diagnostics TAM, while his candid anti-amyloid scorecard frames roughly 30% slowing as 'the beginning,' comparing the moment to where AZT stood for HIV. ## The Neuro & Alzheimer's Pipeline ### Week of June 28, 2026: pTau-217 Blood Tests Go Direct to Consumer as Anti-Amyloid Stays Early Innings --- ## TL;DR - A prescribing Alzheimer's clinician says pTau-217 blood tests are now sold direct-to-consumer by "quite a few" labs, but warns the DTC versions aren't validated like the FDA-cleared one, and none are reliable yet in asymptomatic people. A quality/trust gap is opening underneath a real TAM. - Same clinician's candid anti-amyloid scorecard: it's the only way to clear plaque to PET-negative, but ~30% slowing is "the beginning," not the destination, "we are where AZT was for HIV." He prescribes to "many," not all. ## What's new **Blood biomarkers are quietly going retail, and not all of them are good.** On [Brain Talk | Being Patient](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjEZDivKSkhAnDJsyP5xB821lHUN4joXLBLDS-2FRfCdn9XhRAVnG-2Bxcw-2BafKubGzXJOhcgOidcBZXzkRH-2ByDN-2Fqd9KqAIYXcyn68hOnkf1fajw-3D-3Duq48_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbV8AOl04MZC1PXgD5AuZP9NjxDerfQeRXa8GyRBpXKF24U6Hp2iwWVU8UDzccHVbkzDdgEbdZCjr7vLh6ZZGOpINMkbQBe9uujFdpuJQoJyJ2OXPKaTRqh-2F7zmV-2FQAhUkiTOGIm5AVuipBredBL5ROBs63ymweUEyQjbTXn4C097Q-3D-3D) (June 23), Dr. Nathaniel Chin, a University of Wisconsin geriatrician who actually writes these scripts (OPERATOR), said "there are quite a few blood testing companies that are offering pTau-217 now" direct-to-consumer, comparing the arc to DTC genetic testing. The warning that matters for the names: "Not all tests are created equal," the FDA-cleared assay validated in MCI and dementia is not what "you might be able to get down the street," and none are reliable yet in pre-symptomatic people. *Why it moves numbers:* the bull case for Quanterix, C2N, Roche, Fujirebio, and Labcorp/Quest rests on pTau-217 becoming the front door to treatment. Commoditization widens the funnel but compresses price and puts a premium on the validated, reimbursed test, exactly the split Chin is describing. **The most honest anti-amyloid scorecard you'll hear from someone writing the prescriptions.** Same episode, same speaker (OPERATOR): the two Phase 3 programs were "very well conducted," and clearing amyloid to a negative PET scan is something "no other intervention" can do, "a pretty remarkable accomplishment." But: "we just don't see the clinical benefit that we're hoping for." He frames ~30% slowing as meaningful-but-early, "we are where AZT was for HIV... we're just at the beginning," and expects real-world data past 18 months to show treated/untreated curves keep separating. In Wisconsin "we prescribe these medications, not for everyone, but for many." *Why it matters:* this is the demand-side reality beneath the Leqembi/Kisunla ramp, measured adoption, not a dam breaking. **A non-amyloid counter-narrative got a louder microphone than the drugs did.** On [Alzheimer's Breakthrough](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjQo4ApLkOWRhjmoKVrX61QX6pSYS2VDVW1-2FW3Npg5RSmNe3nE2OIeRyFHPqy-2FlHGAaqpbsWifU79JmNwqI0QBExwUEK2KszejTxrXGp-2FT8Lg-3D-3DGffY_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbV8AOl04MZC1PXgD5AuZP9NjxDerfQeRXa8GyRBpXKF28iOfI22Y8xdW6p05x3DLyfO-2FET6Knk1Mi9X3vAP4TJuwWkzatW9ORq-2Bg8nbo6VWr-2BS-2Bq1IbtqTtOdpolEPrNzaZAP0fpXPj6eFRP9nb2go4cdI5Y-2FHJfUvofJv6Kr8gkw-3D-3D) (June 25), trial investigators Dr. Josh Helman and Dr. Craig Tanio (OPERATOR, but caveat hard) walked through their "Evanthea" precision-medicine/lifestyle trial: ~90% of patients improved, north of a full standard deviation on CNS Vital Signs cognitive testing at nine months, versus decline in controls. They anchored explicitly against the drugs, "monoclonal antibodies cost $85,000," and floated Medicare paying via a global fee under coverage-with-evidence-development. *Caveat:* sub-$10M study, peer review pending, small and unblinded. Not investable. But it's the cheap "treat-the-whole-system" story that gains oxygen every quarter the drugs underwhelm, and a reminder that the CED/registry framework is the payer battleground. **Lilly's tape, not Lilly's pipeline.** On [Stock Market Today With IBD](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg5U3ivst2iegBu-2B4QTq8tdScLXKZZCkAu-2B4MFf6im-2BHE8Fk0vw-2FV8XpM593ZgmMnPC9evhJFtd5EmUCChlu0N-2F8AZ-2BBUdW7XStWYEXLdjAiQ-3D-3DmJbt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbV8AOl04MZC1PXgD5AuZP9NjxDerfQeRXa8GyRBpXKF2zwAYy39UZPzjG5Ed63HxUeMXQ-2FWt18fm0rkqQw5K-2BDr-2BDxJjrrPWP1oPULzbTTXG9CBQ6RzIK1geBlWSR-2BNtDgrDXwYMKJ-2FxLiUQtSf3W0xbxSK-2BMD3jiMEWoPrHyEyKQ-3D-3D) (June 26), the hosts (PUNDIT) flagged LLY up ~7% in a session, roughly two average true ranges, an "abnormally large move," on rotation into healthcare/pharma, and suggested IBB/XBI for those who don't want single-name biotech risk. No Kisunla, no donanemab, no payer color. Momentum, not fundamentals: tape, not thesis. ## The debate *Does sub-Q dosing + blood biomarkers + broadening coverage turn anti-amyloid into a multi-billion franchise, or do modest efficacy, ARIA, and diagnostic bottlenecks keep uptake structurally weak while the tau bets stay unproven?* **Bull (steel-manned from Chin):** removing amyloid is real and unique; ~30% slowing compounds over time; the field is "building momentum"; biomarkers created the early-intervention window. A cheaper blood front-door plus more clinicians comfortable prescribing widens the funnel structurally. **Bear (also from Chin, and from the diagnostics warning):** clinical benefit sits below what physicians "hoped for," patients still decline, and the burden makes many opt out. The diagnostic layer meant to feed the funnel is fragmenting into validated-vs-DTC, and the infrastructure to act on a positive test "isn't there yet." Meanwhile the loudest growth in patient-facing media this week was lifestyle reversal, not the drugs. ## Stocks in play - **LLY**: *Bull:* healthcare rotation, ~7% session pop, relative strength. *Bear:* a chart story; no Kisunla launch data on the tape. *Next catalyst:* Q2 earnings / Kisunla script trends. (IBD, June 26) - **QTRX, Roche, Fujirebio, Labcorp/Quest, C2N**: *Bull:* pTau-217 going mainstream expands volume. *Bear:* DTC commoditization + validation gap pressures pricing and trust. *Catalyst:* guideline/payer adoption of the FDA-cleared assay. (Brain Talk, June 23) ## Read-throughs - **Blood diagnostics (QTRX, C2N, Roche, Fujirebio):** mainstreaming is bullish for volume, but the "not all tests are equal" split favors the validated/reimbursed assay. (Brain Talk, June 23) - **PET imaging (LNTH, GEHC):** Chin still treats PET as the confirmatory standard a positive blood test routes to, supports the confirmatory-scan thesis. No direct LNTH/GEHC commentary this week. (Brain Talk, June 23) - **Broader CNS / Parkinson's:** an alternative-medicine show, [Finding Genius Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhigdukQn51Vx5DisqbeBsXgtigxOJ9DqCZoz6dUfAQqbAS4BkwxVkAtZ-2FQr6L-2FrqIDZbyYdmX9-2Bv7DrnBwspMjDHwbUVW42RCtD86hi8IoGw-3D-3D_nY9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbV8AOl04MZC1PXgD5AuZP9NjxDerfQeRXa8GyRBpXKF22M8KiUWMFQlE10w-2FGtv04xRSbvzbEDHq6DqZgpmBh5WEnhNkyx6K7V2DPVQN-2FsTFf63CRSzHhDVk7N-2BpI5htW8uUK1-2BR1Vb8SKFgOelHmWx2o5t9tdmh3P-2F9p6xMz0Bsw-3D-3D) (June 26), covered carbidopa-levodopa dyskinesia and LRRK2 subtypes. Fringe, flagged, not investable.